XYNOMIC PHARMACEUTICALS HOLDINGS, INC.

Xynomic Pharmaceuticals Holdings, Inc., trading on Nasdaq under the ticker XYN, is a clinical-stage biopharmaceutical company that completed its de-SPAC business combination and began trading as a public entity in 2018, with its operations centered in China and its pipeline focused on oncology drug development. The company filed its annual report on Form 10-K with the SEC on March 5, 2019, covering fiscal year 2018, representing one of its first full reporting cycles as a publicly listed entity following its SPAC merger. Xynomic's drug development program targets cancer therapies, placing it within the life sciences and biopharmaceutical sector. For complete sponsor details, deal history, and filing data on XYN, sign up for full access at SpacDesk.